FDA Approves Exelon Patch for Severe Alzheimer’s

The US Food and Drug Administration has approved an expanded indication for the rivastigmine transdermal system (Exelon Patch, Novartis Pharmaceuticals Corporation) to include patients with severe disease. Approval of this new indication for the 13.3 mg/24h dose rivastigmine patch means it can be used across all stages of disease, making it the only transdermal therapy…